The effect of empagliflozin on cardiac function and structure in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis
Abstract
Introduction: Empagliflozin was shown to improve the clinical outcomes of cardiovascular diseases; however, its effects on cardiac structure and cardiac remodeling in patients with heart failure remain controversial to some extent. Aim:We conducted this meta-analysis to compare the effect of empagliflozin with placebo on cardiac structure and function among patients with heart failure.Methods: PubMed, Scopus, Web of Science, and the Cochrane Library were systematically searched from inception to December 20, 2024, to identify randomized controlled trials comparing the effects of empagliflozin with placebo on cardiac structure and function in patients with heart failure.A random-effects model (DerSimonian-Laird) was employed to pool data.Results: Four studies with 234 individuals in the empagliflozin group and 231 individuals in the placebo group were included.Compared to placebo, empagliflozin 10 (mg/day) significantly increased left ventricular ejection fraction (LVEF) (WMD 2.96%, 95% CI (0.84, 5.09), I 2 = 85.28%), decreased left ventricular (LV) end-diastolic volume (WMD -17.05 ml, 95% CI (-23.68,-10.42),I 2 = 13.88%),LV end-diastolic volume index (WMD -7.59 ml/m 2 , 95% CI (-10.08,-5.10),I 2 = 0.00%), LV end-systolic volume (WMD -15.59 ml, 95% CI (-25.89,-5.28),I 2 = 74.69%),LV end-systolic volume index (WMD -6.68 ml/m 2 , 95% CI (-7.95, -5.41),I 2 = 0.00%), and left atrial volume index (WMD -2.16 ml/m 2 , 95% CI (-4.21, -0.10),I 2 = 0.00%), but did not significantly…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 234 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.